RecruitingPhase 1NCT05734196
The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 Deficiency
Studying Autosomal recessive hypophosphatemic rickets
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Inozyme Pharma
- Principal Investigator
- Medical Director, MD, MDBioMarin Pharmaceutical
- Intervention
- INZ-701(drug)
- Enrollment
- 16 enrolled
- Eligibility
- 1 years · All sexes
- Timeline
- 2023 – 2027
Study locations (7)
- Rady Children's Hospital, San Diego, California, United States
- Boston Children's Hospital, Boston, Massachusetts, United States
- Nationwide Children's Hospital, Columbus, Ohio, United States
- The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- The University of Utah, Salt Lake City, Utah, United States
- Hospital Sant Joan de Déu, Barcelona, Spain
- Royal Manchester Children's Hospital, Manchester, United Kingdom
Collaborators
BioMarin Pharmaceutical
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05734196 on ClinicalTrials.govOther trials for Autosomal recessive hypophosphatemic rickets
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07473973ENERGY 2: Evaluation of the Efficacy and Safety of INZ-701 in Infants With ENPP1 DeficiencyInozyme Pharma
- ACTIVE NOT RECRUITINGPHASE3NCT06046820The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 DeficiencyInozyme Pharma
See all trials for Autosomal recessive hypophosphatemic rickets →